Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, you can lose weight on Wegovy — clinical trials show adults using semaglutide 2.4mg alongside a reduced-calorie diet and regular activity lost an average of around 15% of their body weight over 68 weeks. That figure comes from the STEP 1 trial, published in the New England Journal of Medicine, and it tells you something useful: Wegovy works, but it works with you, not instead of you. Semaglutide is a prescription-only medicine, which means a prescriber assesses whether it is clinically appropriate for you before any treatment begins — there is no shortcut around that, nor should there be.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The headline figure (roughly 15% average weight loss over 68 weeks) is worth sitting with for a moment, because averages hide a range. In the STEP 1 trial, some participants lost considerably more; others lost less. What the data make clear is that the people who did best were those who stuck consistently with both the medicine and the lifestyle changes that ran alongside it. That is not a caveat buried in small print; it is baked into the trial design and into Wegovy's UK licence, which specifies use alongside a reduced-calorie diet and increased physical activity.
NICE's appraisal of semaglutide (TA875) reinforces this point: the recommendation is made within a framework of specialist weight-management support, not as a standalone drug intervention. For people wondering whether they can lose weight with Wegovy taken in isolation, the honest answer is that the evidence for it was generated in people who also changed what they ate and how much they moved. The medicine reduces appetite and makes portion control easier, it does not rewrite your habits on its own.
One practical implication: the dose escalation schedule matters. Treatment starts at 0.25mg and rises gradually, typically every four weeks, through 0.5mg, 1mg and 1.7mg before reaching the 2.4mg maintenance dose. Rushing that process to reach a higher dose faster is not supported by the evidence and increases the risk of GI side effects. Your prescriber sets the pace, that is not bureaucracy, it is the clinical rationale behind the results.
You may have heard that Wegovy reduces appetite so dramatically that eating feels irrelevant. For some people, especially early on, that is close to true. But appetite suppression alone does not make the choice of what to eat less important. Protein is a particular priority: on a reduced calorie intake, keeping protein adequate helps preserve muscle mass, and muscle matters for long-term metabolic health and for how you feel day to day. The NHS's healthy weight guidance provides a sound, evidence-based starting framework.
Physical activity is similarly not optional. Strength-based or resistance exercise helps maintain lean tissue as weight comes off, which is something that straightforward calorie restriction without exercise tends to erode. Cardiovascular activity supports heart and metabolic health and reinforces the appetite and mood benefits that many people notice on semaglutide. None of this means you need to be in the gym six days a week, consistent moderate activity, whatever form that takes for you, is what the evidence supports.
Hydration is another area worth attention. GI side effects such as nausea, diarrhoea and vomiting are most common when starting or moving up doses, and they can lead to dehydration if you are not careful. Sipping water steadily through the day is a small habit that makes a real difference, particularly in the first few weeks at each new dose level. If you are wondering how long it typically takes to notice results, that depends on the individual, our guide to when weight loss tends to start on Wegovy covers the timeline in more detail.
The most common side effects of Wegovy are gastrointestinal, nausea, constipation, diarrhoea, reflux, vomiting, and sometimes fatigue. These are typically most noticeable at the start of treatment or after a dose increase, and for most people they ease within days to a couple of weeks. The concern for weight loss is that feeling persistently nauseous can make it hard to eat enough of the right things, and under-eating protein and micronutrients creates its own problems.
A few practical approaches that our prescribers hear work well: eating smaller amounts more frequently, choosing bland foods during the first days after a dose change, avoiding very fatty or spicy meals, and not lying down immediately after eating. These are not substitutes for medical advice, if side effects are severe or persistent, the right move is to contact your clinical team, not to push through alone.
For a broader picture of how semaglutide works on appetite and metabolism at a biological level, our page on semaglutide's mechanism goes into the detail. And if you are already on Wegovy and looking to optimise your results, there is specific guidance on getting more from your treatment.
Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI, though, is only one part of the picture a prescriber considers.
Several factors influence how much weight any individual loses on semaglutide: starting weight, metabolic profile, how consistently the lifestyle components are applied, whether GI side effects disrupt eating, and individual biological variation in GLP-1 response. There is no reliable way to predict in advance exactly where someone will land, which is why the six-month review point (checking for at least 5% weight loss) exists as a formal clinical checkpoint rather than a vague aspiration. People who want to understand what it takes to lose weight quickly on Wegovy will find a detailed breakdown of the factors involved, and those focused on getting the greatest possible results from their treatment can read through the evidence on what consistently separates higher responders from lower ones.
Cost is a question many people have before they start, and it is a fair one. Our Wegovy pricing page sets out what private treatment typically involves. For people curious about how Wegovy compares with other weight-loss treatments, an overview of licensed options is a useful starting point. If you are ready to explore whether Wegovy is clinically appropriate for you, starting a free consultation with our prescribers is the straightforward next step, no commitment, no waiting list, reviewed the same day your answers come in.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.